Skip to main
  1. Stocks
  2. Legend Biotech
  3. Forecast
LEGN

Legend Biotech (LEGN) Stock Forecast & Price Target

Legend Biotech (LEGN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 10%
Buy 40%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Legend Biotech is supported by Carvykti’s durable, best-in-class clinical profile, including 60.5-month median PFS and 69.2% five-year OS, which reinforces its advantage in multiple myeloma and strengthens adoption in 2L/3L and potentially earlier lines. Commercially, the franchise is still growing despite competitive pressure, with management noting 50% of patients now treated in 2L/3L, 80% of patients not BCMA-exposed, and continued expectations for double-digit growth as US and ex-US expansion broaden the opportunity. Financially, 3Q26 revenue of $360M, gross margin in the high 50s, and $853M in cash with cash flow positivity point to improving profitability, lower funding risk, and room for margin expansion.

Bears say

Legend Biotech is highly dependent on Carvykti, so any stumble in CARTITUDE-5/6, slower 2-3L adoption, or manufacturing bottlenecks could materially weaken revenue growth and delay profitability. The company’s 3Q26 US sales were flat QoQ, while management implied 4Q26 revenue of about $722M versus consensus near $740M, signaling only modest sequential improvement and raising concern that the market may be near a growth plateau. With roughly half of 4L+ US revenue still exposed to anito-cel competition starting 1Q27 and broader risks from safety, reimbursement, and regulatory hurdles, its concentrated and high-risk profile supports a negative outlook.

Legend Biotech (LEGN) has been analyzed by 10 analysts, with a consensus rating of Buy. 10% of analysts recommend a Strong Buy, 40% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Legend Biotech and is not a guaranteed prediction by Public.com or investment advice.

Legend Biotech (LEGN) Analyst Forecast & Price Prediction

Get the latest Legend Biotech (LEGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Legend Biotech (LEGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Legend Biotech (LEGN) Forecast

Analysts have given Legend Biotech (LEGN) a Buy based on their latest research and market trends.

According to 10 analysts, Legend Biotech (LEGN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Legend Biotech (LEGN)


Legend Biotech (LEGN) Analyst Forecast & Price Prediction

Get the latest Legend Biotech (LEGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Legend Biotech (LEGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LEGN stock data and trends